Impact of age and menopausal stage on serum anti-Müllerian hormone levels in middle-aged women

References

• Kuokkanen S, Pal L. Reproductive aging: epidemiology, symptomatology, and nomenclature. In: Pal L, Sayegh RA, editors. Essentials of menopause management. Cham (Switzerland): Springer; 2017. p. 3–12.
   Google Scholar
• Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertil Steril. 2013;99(7):1825–1830.
   PubMed Web of Science ®Google Scholar
• Broer SL, Broekmans FJ, Laven JS, et al. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370–385.
   PubMed Web of Science ®Google Scholar
• Gracia CR, Shin SS, Prewitt M, et al. Multi-center clinical evaluation of the access AMH assay to determine AMH levels in reproductive age women during normal menstrual cycles. J Assist Reprod Genet. 2018;35:1–7.
   PubMed Web of Science ®Google Scholar
• Hansen KR, Craig LTB, Zavy MT, et al. Ovarian primordial and nongrowing follicle counts according to the Stages of Reproductive Aging Workshop (STRAW) staging system. Menopause. 2012;19(2):164–171.
   PubMed Web of Science ®Google Scholar
• Harlow SD, Gass M, Hall JE, STRAW + 10 Collaborative Group, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15(2):105–114.
   PubMed Web of Science ®Google Scholar
• Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–395.
   PubMed Web of Science ®Google Scholar
• Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril. 2012;97(4):843–851.
   PubMed Web of Science ®Google Scholar
• Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168.
   PubMed Web of Science ®Google Scholar
• Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril. 2011;95(2):747–750.
   PubMed Web of Science ®Google Scholar
• Tehrani FR, Mansournia MA, Solaymani-Dodaran M, et al. Age-specific serum anti-Müllerian hormone levels: estimates from a large population-based sample. Climacteric. 2014;17(5):591–597.
   PubMed Web of Science ®Google Scholar
• Segawa T, Omi K, Watanabe Y, et al. Age-specific values of access anti-Müllerian hormone immunoassay carried out on Japanese patients with infertility: a retrospective large-scale study. BMC Womens Health. 2019;19:57.
   PubMed Web of Science ®Google Scholar
• de Kat AC, van der Schouw YT, Eijkemans MJC, et al. Back to the basics of ovarian aging: a population-based study on longitudinal anti-Müllerian hormone decline. BMC Med. 2016;14(1):151.
   PubMedGoogle Scholar
• Helden JV, Weiskirchen R. Age-independent anti-Müllerian hormone (AMH) standard deviation scores to estimate ovarian function. Eur J Obstet Gynecol Reprod Biol. 2017;213:64–70.
   PubMed Web of Science ®Google Scholar
• Du X, Ding T, Zhang H, et al. Age-specific normal reference range for serum anti-Müllerian hormone in healthy Chinese Han women: a nationwide population-based study. Reprod Sci. 2016;23(8):1019–1027.
   PubMed Web of Science ®Google Scholar
• Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478–3483.
   PubMed Web of Science ®Google Scholar
• Iwase A, Nakamura T, Osuka S, et al. Anti-Müllerian hormone as a marker of ovarian reserve: what have we learned, and what should we know? Reprod Med Biol. 2016;15(3):127–136.
   PubMedGoogle Scholar
• Iwase A, Osuka S, Goto M, et al. Clinical application of serum anti-Müllerian hormone as an ovarian reserve marker: a review of recent studies. J Obstet Gynaecol Res. 2018;44(6):998–1006.
   PubMed Web of Science ®Google Scholar
• Hudson PL, Dougas I, Donahoe PK, et al. An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab. 1990;70(1):16–22.
   PubMed Web of Science ®Google Scholar
• Gassner D, Jung R. First fully automated immunoassay for antiMüllerian hormone. Clin Chem Lab Med. 2014;52:1143–1152.
   PubMed Web of Science ®Google Scholar
• Demirdjian G, Bord S, Lejeune C, et al. Performance characteristics of the Access AMH assay for the quantitative determination of anti-Müllerian hormone (AMH) levels on the Access* family of automated immunoassay systems. Clin Biochem. 2016;49(16–17):1267–1273.
   PubMed Web of Science ®Google Scholar
• Pearson K, Long M, Prasad J, et al. Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA. Reprod Biol Endocrinol. 2016;14:8.
   PubMed Web of Science ®Google Scholar
• Jung S, Allen N, Arslan AA, et al. Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women. Fertil Steril. 2017;107(4):1012–1022.
   PubMed Web of Science ®Google Scholar
• Dólleman M, Verschuren WMM, Eijkemans MJC, et al. Reproductive and lifestyle determinants of anti-Müllerian hormone in a large population-based study. J Clin Endocrinol Metab. 2013;98(5):2106–2115.
   PubMed Web of Science ®Google Scholar
• Amer SAKS, James C, Al-Hussaini TK, et al. Assessment of circulating anti-Müllerian hormone in women using hormonal contraception: a systematic review. J Womens Health (Larchmt). 2020;29(1):100–110.
   PubMed Web of Science ®Google Scholar
• Landersoe SK, Birch Petersen K, Sørensen AL, et al. Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives. Reprod Biomed Online. 2020;40(1):176–186.
   PubMed Web of Science ®Google Scholar
• Bernardi LA, Carnethon MR, de Chavez PJ, et al. Relationship between obesity and anti-Müllerian hormone in reproductive-aged African American women. Obesity (Silver Spring). 2017;25(1):229–235.
   PubMed Web of Science ®Google Scholar
• Jaswa EG, Rios JS, Cedars MI, et al. Increased body mass index is associated with a nondilutional reduction in antimüllerian hormone. J Clin Endocrinol Metab. 2020;105:3234–3242.
   Web of Science ®Google Scholar
• Plante BJ, Cooper GS, Baird DD, et al. The impact of smoking on antimüllerian hormone levels in women aged 38 to 50 years. Menopause. 2010;17(3):571–576.
   PubMed Web of Science ®Google Scholar
• Schuh-Huerta SM, Johnson NA, Rosen MP, et al. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod. 2012;27(2):594–608.
   PubMed Web of Science ®Google Scholar
• Simões-Pereira J, Nunes J, Aguiar A, et al. Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit. Endocrine. 2018;61:144–148.
   PubMed Web of Science ®Google Scholar